First Time Loading...
E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 24.95 HKD -1.96% Market Closed
Updated: May 6, 2024

Everest Medicines Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Everest Medicines Ltd
Cash from Financing Activities Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
E
Everest Medicines Ltd
HKEX:1952
Cash from Financing Activities
¥10.1m
CAGR 3-Years
-88%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Financing Activities
-¥448.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Financing Activities
¥2.9B
CAGR 3-Years
-16%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Financing Activities
-¥893.3m
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Financing Activities
-¥2.4B
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
-39%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Financing Activities
-¥374.2m
CAGR 3-Years
-104%
CAGR 5-Years
-98%
CAGR 10-Years
N/A

See Also

What is Everest Medicines Ltd's Cash from Financing Activities?
Cash from Financing Activities
10.1m CNY

Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Cash from Financing Activities amounts to 10.1m CNY.

What is Everest Medicines Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-53%

The average annual Cash from Financing Activities growth rates for Everest Medicines Ltd have been -88% over the past three years , -53% over the past five years .